Get the Stockscreener App
3.96
3.66%
+0.14
After Hours:
3.95
-0.010
-0.25%
Akoya Biosciences Inc stock is currently priced at $3.96, with a 24-hour trading volume of 114.14K.
It has seen a +3.66% increased in the last 24 hours and a -13.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.81 pivot point. If it approaches the $3.98 resistance level, significant changes may occur.
Previous Close:
$3.82
Open:
$3.86
24h Volume:
114.14K
Market Cap:
$195.55M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-2.0102
EPS:
-1.97
Net Cash Flow:
$-54.55M
1W Performance:
+3.94%
1M Performance:
-13.16%
6M Performance:
+16.13%
1Y Performance:
-43.35%
1D Range:
$3.83
$4.10
52W Range:
$3.04
$8.80
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855-896-8401
Address
100 Campus Drive, 6th Floor, Marlborough
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
GlobeNewswire Inc.
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
GlobeNewswire Inc.
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
GlobeNewswire Inc.
Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus
Zacks Investment Research
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Zacks Investment Research
Akoya Biosciences Inc Stock (AKYA) Financials Data
Akoya Biosciences Inc (AKYA) Revenue 2024
AKYA reported a revenue (TTM) of $96.63 million for the quarter ending December 31, 2023, a +29.09% rise year-over-year.
Akoya Biosciences Inc (AKYA) Net Income 2024
AKYA net income (TTM) was -$63.32 million for the quarter ending December 31, 2023, a +10.36% increase year-over-year.
Akoya Biosciences Inc (AKYA) Cash Flow 2024
AKYA recorded a free cash flow (TTM) of -$54.55 million for the quarter ending December 31, 2023, a +10.36% increase year-over-year.
Akoya Biosciences Inc (AKYA) Earnings per Share 2024
AKYA earnings per share (TTM) was -$1.46 for the quarter ending December 31, 2023, a +22.34% growth year-over-year.
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
0.69%
0.07%
Cap:
|
Volume (24h):